ArticleThe Journal of antimicrobial chemotherapy2015
Comparative outcomes of β-lactam antibiotics in outpatient parenteral antibiotic therapy: treatment success, readmissions and antibiotic switches.
Article in The Journal of antimicrobial chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Systematic Review and Meta-analysis of the Safety of Antistaphylococcal Penicillins Compared to Cefazolin.Antimicrobial agents and chemotherapy · 2018Pooled it
- Evaluation of the Safety of Cefazolin Monotherapy in Outpatient Parenteral Antimicrobial Therapy at a Large Academic Medical Center.Open forum infectious diseases · 2025Trial
- Clinical and patient-reported outcomes of self-administered outpatient parenteral antimicrobial treatment (S-OPAT): a scoping review.Infection · 2025Article
- Propensity Score-Weighted Analysis of the Impact of Outpatient Parenteral Antimicrobial Therapy Plan Reconciliation on Unscheduled Care.Open forum infectious diseases · 2025Article
- Current practices in outpatient parenteral antimicrobial therapy programmes: an international multi-centre survey.JAC-antimicrobial resistance · 2025Article
- Current practices and challenges of outpatient parenteral antimicrobial therapy: a narrative review.The Journal of antimicrobial chemotherapy · 2024Review
- Improving antimicrobial treatment in terms of antimicrobial stewardship and health costs by an OPAT service.Infection · 2024Article
- Creation and Validation of an Automated Registry for Outpatient Parenteral Antibiotics.Open forum infectious diseases · 2024Article
- Serious Adverse Events and Laboratory Monitoring Regimens for Outpatient Parenteral Antimicrobial Therapy With Cefazolin and Ceftriaxone.Open forum infectious diseases · 2023Article
- Usefulness of Routine Laboratory Tests for Follow up of Patients Receiving Outpatient Parenteral Antimicrobial Therapy Run by Infectious Diseases Fellows.Antibiotics (Basel, Switzerland) · 2023Article
- Conventional Hospitalization versus Sequential Outpatient Parenteral Antibiotic Therapy forAntibiotics (Basel, Switzerland) · 2023Article
- A Quality Initiative to Improve Postdischarge Care for Patients on Outpatient Parenteral Antimicrobial Therapy.Open forum infectious diseases · 2022Article
- Clinical Outcomes of an Innovative Cefazolin Delivery Program for MSSA Infections in OPAT.Journal of clinical medicine · 2022Article
- Risk Factors Associated With Nephrotoxicity During Outpatient Intravenous Vancomycin Administration.The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2022Article
- The Impact of a Standardized Discharge Process on 30-Day Readmissions for Patients on Outpatient Parenteral Antibiotic Treatment.Hospital pharmacy · 2022Article
- Risk of Neutropenia in Adults Treated with Piperacillin-Tazobactam or Cefazolin: A Retrospective Cohort Study.The Canadian journal of hospital pharmacy · 2022Article
- A Narrative Review of Early Oral Stepdown Therapy for the Treatment of UncomplicatedOpen forum infectious diseases · 2020Review
- Perspectives of Patients on Outpatient Parenteral Antimicrobial Therapy: Experiences and Adherence.Open forum infectious diseases · 2020Article
- Evaluation of Inpatient Antimicrobial Regimens for Readmitted Outpatient Parenteral Antimicrobial Therapy Patients Receiving Daptomycin or Ertapenem for Ease of Administration.Open forum infectious diseases · 2019Article
- Perspectives of United States-based Infectious Diseases Physicians on Outpatient Parenteral Antimicrobial Therapy Practice.Open forum infectious diseases · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
objectivesβ-Lactam antibiotics are commonly used in outpatient parenteral antimicrobial therapy (OPAT), but data regarding outcomes of long-term therapy are limited. The purpose of this study was to compare treatment success, readmission and antibiotic switch rates in patients treated with β-lactam antibiotics as OPAT.
methodsWe carried out a retrospective review of all patients, discharged from Tufts Medical Center with cefazolin, ceftriaxone, ertapenem or oxacillin, between January 2009 and June 2013. A competing risks analysis was used to compare the cumulative incidence of first occurrence of treatment success, antibiotic switch and 30 day readmission for each drug.
resultsFour hundred patients were identified (cefazolin n = 38, ceftriaxone n = 104, ertapenem n = 128 and oxacillin n = 130). Baseline demographics were similar. Treatment success rates were higher for ceftriaxone and ertapenem (cefazolin 61%, ceftriaxone 81%, ertapenem 73% and oxacillin 58%; P < 0.001). Thirty-day all-cause readmissions were similar (cefazolin 21%, ceftriaxone 14%, ertapenem 20% and oxacillin 15%; P = 0.46). In 400 OPAT courses, 37 out of 50 antibiotic switches were accomplished without readmission. Adverse drug events (ADEs) were the most common reason for outpatient antibiotic switches (31/37, 84%). The ADE rate was higher for the oxacillin group (cefazolin 2.0 versus ceftriaxone 1.5 versus ertapenem 2.9 versus oxacillin 8.4 per 1000 OPAT days; P < 0.001).
conclusionsOPAT with β-lactam antibiotics is effective, but antibiotic switches for adverse events were more frequent with oxacillin use. Clinicians should be cognizant of the risk of readmissions and ADEs in OPAT patients, as the value of OPAT lies in reducing patient morbidity and readmissions by managing ADEs and preventing clinical failures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.